Thu.Jul 18, 2024

article thumbnail

The Girls Are Back: One Pharmacist’s Journey to Save His Community Pharmacy

Drug Topics

Mayank Amin, PharmD, RPh, MBA, sat down with Drug Topics on part 1 of an episode of Over the Counter to share his experiences transforming a shuttered independent pharmacy into a thriving community hub.

article thumbnail

Notable Comorbidities and Unmet Needs in Pediatric Asthma

Pharmacy Times

The authors emphasize that clinical research should focus on real-world difficulties, and pediatric asthma control should be seen as a health care priority.

153
153
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

PBM Reform Law Aims to Support Local Pharmacies in Pennsylvania

Drug Topics

House Bill (HB) 1993 seeks to increase PBM transparency and accountability in an effort to combat the rising cost of prescription drugs.

236
236
article thumbnail

Lomecel-B CLEARMIND Phase 2a Trial Results to Be Presented at AAIC

Pharmacy Times

Safety and efficacy findings on Lomecel-B will be presented at the upcoming 2024 Alzheimer’s Association International Conference, which will be held July 28 to August 1.

139
139
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Optum lays off more employees at Landmark, OptumInsight

Fierce Healthcare

The sprawling enterprise that is UnitedHealth Group is undergoing more layoffs under its Optum umbrella. | UnitedHealth's Optum is again laying off workers, with the scope unconfirmed. Landmark Health is downsizing once again and leaving major metropolitan areas.

141
141
article thumbnail

Opinion: IRBs fail to assess trials’ scientific merit, putting participants at risk

STAT

Thousands of people volunteer for clinical research trials in the United States every year. They put their bodies on the line, often seeking benefits from experimental treatments because existing care is ineffective. For most clinical trials, independent institutional review boards (IRBs) are legally required to review the protocol before enrollment can begin.

136
136

More Trending

article thumbnail

STAT+: Broad Institute, facing end of Microsoft cloud contract, shuffles data science leadership

STAT

The Broad Institute of MIT and Harvard is perhaps best known for the trailblazing work coming out of the labs of its core members; CRISPR tools like David Liu’s prime and base editors , Feng Zhang’s virus-like drug delivery particles , or Pardis Sabeti’s network of low-cost diagnostics designed to catch the next pandemic before it starts.

136
136
article thumbnail

Man of Heal: The Story of the Superman Pharmacist

Drug Topics

In part 2 of the latest episode of Over the Counter, Mayank Amin, PharmD, RPh, MBA, discusses his journey as the Superman Pharmacist and expresses hope for the future of community pharmacy.

article thumbnail

Massive study of veterans’ DNA shows how diversity can help researchers decipher the genome

STAT

An expansive new study offers clear evidence that sequencing the genomes of diverse populations can yield fresh insights into how our DNA shapes our health. A team of researchers involved in an ongoing project spearheaded by the U.S. Department of Veterans Affairs analyzed data from nearly 636,000 veterans to look for genetic variants associated with more than 2,000 traits, such as height, blood glucose levels, and whether subjects had certain cancers.

article thumbnail

The states with the best and worst women's health outcomes, per new scorecard

Fierce Healthcare

A new nationwide scorecard ranks the state of women’s health and reproductive care. The results reveal a deep geographic divide in women’s healthcare access and outcomes. | The state-by-state rankings found “significant” disparities between states and deepening racial and ethnic gaps in outcomes. The findings suggest these gaps could widen further, especially for women of color and those with low incomes in states with restricted access to reproductive care.

131
131
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

‘Legal’ psychedelic mushrooms actually contain illegal hallucinogens, study shows

STAT

WASHINGTON – A new study published Thursday finds that several mushroom candies, which are widely promoted as containing legal psychedelic ingredients, actually contain illegal hallucinogens. The study sampled products sold in gas stations and smoke shops near Charlottesville, Va. It identified the Schedule I drug psilocin in mushroom candies sold under the brand names Diamond Shruumz and Wonderland Legal Psychedelics.

article thumbnail

Sports Pharmacy Network attends the 2024 National Athletic Trainers Association (NATA) Clinical Symposia & Expo

Pharmacy Times

The SPN team's key focus was collaborating with the sports medicine community and discussing ways Sports Pharmacy can support athletic trainers in creating comprehensive care for athletes.

123
123
article thumbnail

Intermittently Scanned CGM Can Reduce Hypoglycemic Episodes in T1D

Drug Topics

Patients using isCGM had reduced glucose variability, time in low glucose range, time in very low glucose range, and less events related to low glucose levels.

112
112
article thumbnail

Intermountain to use NeuroFlow tech to support integrated behavioral health in primary care

Fierce Healthcare

Intermountain Health and NeuroFlow have teamed up to bring behavioral health screening and analytics to primary care patients in Colorado. | NeuroFlow will integrate behavioral health analytics into care workflows and engage patients with relevant digital resources and interventions. It will also provide suicide prevention services to patients and offer outreach from trained crisis professionals.

126
126
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

STAT+: Startup Q Bio raises $27 million to build its own full-body scanner

STAT

A prevention-focused co-founded by the head of a Stanford research lab is making an expensive bet with its latest fundraise: that it can build a better full-body scanner than medical device behemoths selling MRIs to health systems. Palo Alto-based Q Bio raised $27 million in “strategic funding” from existing investors including Khosla Ventures, Andreessen Horowitz, and Founders Fund, the company shared with STAT exclusively.

124
124
article thumbnail

Boehringer Ingelheim, GoodRx team to boost access to Humira biosimilars

Fierce Healthcare

GoodRx is joining forces with drugmaker Boehringer Ingelheim to make its Humira biosimilar adalimumab available at an affordable price. | GoodRx is joining forces with drugmaker Boehringer Ingelheim to make its Humira biosimilar adalimumab available at an affordable price.

125
125
article thumbnail

Pfizer's ATTR heart disease drug needs hefty discount, says ICER draft report. What about Alnylam's Amvuttra?

Fierce Pharma

Pfizer’s blockbuster drug tafamidis for the treatment of the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM) needs at least a 96% discount off its list price to be considered cost | Pfizer’s blockbuster tafamidis for the treatment of the rare heart disease ATTR-CM needs at least a 96% discount off its list price to be considered cost-effective under common benchmarks, a draft report by ICER has found.

121
121
article thumbnail

Hospitals push back on CMS' proposed mandatory organ transplant model

Fierce Healthcare

The hospital industry is warning that a proposed mandatory model for kidney transplants could introduce “unnecessary disruption and uncertainty to the transplant ecosystem” and ultimately undercut | Hospital lobbyists wrote that the Increasing Organ Transplant Access (IOTA) Model "is not fully developed and contains fundamental flaws” that would lead to a “potential negative impact on patient outcomes.

Hospitals 122
article thumbnail

Researchers Identify the Neurological Mechanism Behind Anorexia Nervosa

Pharmacy Times

Acetylcholine deficit observed in patients with anorexia nervosa suggest potential targeted treatment options.

144
144
article thumbnail

Efanesoctocog alfa Prophylaxis Offers “Efficacious Prevention” to Children With Severe Hemophilia A

Drug Topics

The drug was FDA approved as antihemophilic factor (recombinant), Fc-VWF-XTEN Fusion Protein-ehtl (Altuviiio) in February 2023.

FDA 112
article thumbnail

Recap: Pharmacy Times Covers the Pharmacy Quality Alliance Annual Meeting

Pharmacy Times

The Pharmacy Quality Alliance Annual Meeting highlighted social determinants of health, oral oncolytics, and screening opportunities.

122
122
article thumbnail

Emporos, InterLink AI Partnership to Revolutionize POS in the Pharmacy

Drug Topics

Emporos announced a strategic partnership with InterLink AI to help pharmacists streamline tasks and fill more prescriptions.

112
112
article thumbnail

PBMs will face House committee grilling next week

pharmaphorum

The House Committee on Oversight and Accountability will quiz leaders of pharmacy benefit managers (PBMs) at a hearing next week, amid scrutiny of the sector's role in rising healthcare costs in the US.The hearing – scheduled for 23rd July – is part of an ongoing investigation by the committee into PBMs' alleged anticompetitive practices launched last year and spearheaded by chairman James Comer (R-Ky).

109
109
article thumbnail

With FDA Approval, Vonoprozan Offers Options for Nonerosive GERD

Drug Topics

The approval offers a first of its kind treatment option for patients living with nonerosive GERD.

FDA 112
article thumbnail

Clinical development rates are falling - but it’s not all bad news

pharmaphorum

While clinical development rates are falling, there is still hope in the Phase I bio sector. Learn more about the potential opportunities and positives in this challenging trend.

107
107
article thumbnail

STAT+: Novartis not ready to admit a $3 billion mistake

STAT

This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up  here  to get it delivered to their inbox. Hello! It’s so damn hot. Apologies for the delay in delivery this morning, but I wanted to include a Novartis-pelabresib update from its earnings announcement. It’s the lead item below.

99
article thumbnail

Amidst Uptick in Cases, Investigational Lyme Disease Vaccine Trial Underway

Drug Topics

All participants in the phase 3 clinical trial have completed their primary vaccination series.

Vaccines 112
article thumbnail

Opinion: Real-time vital signs data: a hidden source of value in medical AI

STAT

If data represents the next gold rush for health care, a vast treasure trove of it slips away every day. The increased enthusiasm for AI has led to significant investments in novel solutions for health care, with data coming from a variety of sources such as medical charts, imaging, literature, guidelines, and the like. A largely untapped source of valuable data is staring health care practitioners like myself right in the face: monitors that track vital signs.

article thumbnail

J&J IRA pricing offer is in, as it sticks with 2025 guidance

pharmaphorum

J&J has three of its top-selling drugs in Medicare pricing negotiations but does not expect a major hit to its finances next year

111
111
article thumbnail

STAT+: Pharmalittle: We’re reading about Gilead’s CMO leaving, Novartis hedging on a drug, and more

STAT

Top of the morning to you, and a fine one it is, despite the gray skies hovering over the Pharmalot campus. We are doing our best to maintain sunny spirits, though, because we recall a bit of insight from the Morning Mayor, who taught us that “Every new day should be unwrapped like a precious gift.” To celebrate the notion, we are brewing still more cups of stimulation and inviting you to join us.

article thumbnail

FDA launches new rare disease innovation hub

Pharmaceutical Technology

The new hub will act as a central point of connection and engagement for the rare disease community for FDA-related concerns.

FDA 111
article thumbnail

Boehringer backs Brainomix AI software for lung fibrosis

pharmaphorum

Boehringer Ingelheim has joined forces with digital health firm Brainomix on a project to improve the care of people with fibrosing lung diseases

102
102
article thumbnail

Novartis CEO sees IRA impact ‘manageable’ in short run, maintains midterm growth goal

Fierce Pharma

As biopharma companies and the U.S. | As biopharma companies and the U.S. government near the deadline of their drug price talks under the Inflation Reduction Act, Novartis CEO said the cost cuts “might be manageable” in the short term for the firm’s first few products to be included.

88
article thumbnail

Re-elected von der Leyen pledges EU measures for biotech

pharmaphorum

Ursula von der Leyen highlights biotech and AI as key sectors in speech as she is re-elected as President of the European Commission

103
103